Browsing by Author "Gurbuz, Venhar"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Article Invasive Pneumococcal Infection Due To Serotype 15a After the Pneumococcal Conjugate Vaccine Implementation in Turkey(Taylor & Francis inc, 2017) Buyukcam, Ayse; Guducuoglu, Huseyin; Karaman, Kamuran; Gurbuz, Venhar; Aliyev, Emil; Kara, Ates; Ceyhan, MehmetInvasive pneumococcal infections among children are a serious public health problem in many countries, including Turkey. Pneumococcal conjugate vaccine has been included in Turkey's National Immunization Programme since 2009. We report the first two pediatric cases of invasive pneumococcal infection due to non-vaccine serotype 15A after pneumococcal conjugate vaccine implementation in Turkey. It is essential to monitor the countries' own local seroepidemiologic data for detecting selective pressure of non-vaccine serotypes of S. pneumonia.Article Meningitis Caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae During 2005-2012 in Turkey a Multicenter Prospective Surveillance Study(Taylor & Francis inc, 2014) Ceyhan, Mehmet; Gurler, Nezahat; Ozsurekci, Yasemin; Keser, Melike; Aycan, Ahmet Emre; Gurbuz, Venhar; Coskun, YavuzSuccessful vaccination policies for protection from bacterial meningitis are dependent on determination of the etiology of bacterial meningitis. Cerebrospinal fluid (CSF) samples were obtained prospectively from children from 1 month to <= 18 years of age hospitalized with suspected meningitis, in order to determine the etiology of meningitis in Turkey. DNA evidence of Neisseria meningitidis (N. meningitidis), Streptococcus pneumoniae (S. pneumoniae), and Hemophilus influenzae type b (Hib) was detected using multiplex polymerase chain reaction (PCR). In total, 1452 CSF samples were evaluated and bacterial etiology was determined in 645 (44.4%) cases between 2005 and 2012; N. meningitidis was detected in 333 (51.6%), S. pneumoniae in 195 (30.2%), and Hib in 117 (18.1%) of the PCR positive samples. Of the 333 N. meningitidis positive samples 127 (38.1%) were identified as serogroup W-135, 87 (26.1%) serogroup B, 28 (8.4%) serogroup A and 3 (0.9%) serogroup Y; 88 (26.4%) were non-groupable. As vaccines against the most frequent bacterial isolates in this study are available and licensed, these results highlight the need for broad based protection against meningococcal disease in Turkey.